by Elec23 | Aug 23, 2024 | News&events
A new study suggests that antibodies produced by vaccinia-based vaccines may neutralize the Monkeypox virus, suggesting potential cross-protection against new threats. The findings emphasize VisMederi’s capability to aid in vaccine development and research...
by Elec23 | Aug 7, 2024 | News&events
VisMederi has been successfully qualified by Qualifyze for conducting activities according to GCLP (Good Clinical Laboratory Practices). Both our laboratory facilities have achieved the prestigious SILVER rating! This outstanding result once again reflects our utmost...
by Elec23 | Jun 4, 2024 | News&events
At the heart of research and innovation, the Vismederi Foundation warmly welcomed a group of American students from Kent State University at the Toscana Life Sciences Foundation auditorium on June 4th. This annual event strengthens the collaboration between VisMederi...
by Elec23 | May 22, 2024 | News&events
The eighth edition of the “Influenza Vaccines for the World—IVW 2024” conference and exhibition is currently taking place in Siena (May 21–23, 2024). This event brings together world-renowned experts in the field of influenza vaccines and related issues...
by Elec23 | Apr 16, 2024 | News&events
Simone Paletti, Chief Financial Officer at VisMederi Group, recently attended a key finance forum in Milan organized by “Comunicazione Italiana”. This event served as a crucial meeting point for professionals in Corporate Finance, including Chief Financial...
